Jon Chesebrough

606 total citations
10 papers, 426 citations indexed

About

Jon Chesebrough is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Jon Chesebrough has authored 10 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Immunology. Recurrent topics in Jon Chesebrough's work include CAR-T cell therapy research (3 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Jon Chesebrough is often cited by papers focused on CAR-T cell therapy research (3 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Jon Chesebrough collaborates with scholars based in United States, United Kingdom and Netherlands. Jon Chesebrough's co-authors include Jonathan Rios‐Doria, Leslie Wetzel, Raymond Rothstein, Robert E. Hollingsworth, Ching Ching Leow, Wei Zhao, Nicholas Holoweckyj, Nicholas M. Durham, Bahija Jallal and Yong S. Chang and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Jon Chesebrough

9 papers receiving 409 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jon Chesebrough United States 6 204 186 109 75 73 10 426
Manuela Lacerda Portugal 11 149 0.7× 170 0.9× 36 0.3× 39 0.5× 24 0.3× 14 398
Kirat Kumar Ganguly India 8 158 0.8× 211 1.1× 64 0.6× 11 0.1× 24 0.3× 14 416
Margreet Lang Netherlands 5 184 0.9× 134 0.7× 48 0.4× 17 0.2× 79 1.1× 7 337
Mariam Gachechiladze Czechia 11 207 1.0× 255 1.4× 66 0.6× 10 0.1× 20 0.3× 30 486
Caterina Malcontenti‐Wilson Australia 13 107 0.5× 112 0.6× 27 0.2× 11 0.1× 46 0.6× 21 426
Linda Mooberry United States 9 66 0.3× 246 1.3× 44 0.4× 27 0.4× 24 0.3× 10 494
Vasilios Papavasiliou Canada 12 180 0.9× 195 1.0× 76 0.7× 10 0.1× 19 0.3× 14 422
Kian Kani United States 12 177 0.9× 245 1.3× 51 0.5× 7 0.1× 87 1.2× 21 438
Camilla Hofström Sweden 9 165 0.8× 124 0.7× 25 0.2× 28 0.4× 274 3.8× 16 350
Katrin Rabold Netherlands 9 229 1.1× 203 1.1× 287 2.6× 16 0.2× 16 0.2× 14 511

Countries citing papers authored by Jon Chesebrough

Since Specialization
Citations

This map shows the geographic impact of Jon Chesebrough's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Chesebrough with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Chesebrough more than expected).

Fields of papers citing papers by Jon Chesebrough

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Chesebrough. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Chesebrough. The network helps show where Jon Chesebrough may publish in the future.

Co-authorship network of co-authors of Jon Chesebrough

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Chesebrough. A scholar is included among the top collaborators of Jon Chesebrough based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Chesebrough. Jon Chesebrough is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Torchia, Maria Letizia Giardino, Ashley A. Merlino, Erin Sult, et al.. (2022). Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy. Cytotherapy. 24(7). 720–732. 7 indexed citations
2.
Gilbreth, Ryan, Cui Chen, Erin Sult, et al.. (2020). 112 Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy. SHILAP Revista de lepidopterología. A69.2–A70. 1 indexed citations
3.
Rios‐Doria, Jonathan, Jay Harper, Raymond Rothstein, et al.. (2017). Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Research. 77(10). 2686–2698. 91 indexed citations
4.
Rios‐Doria, Jonathan, Jay Harper, Raymond Rothstein, et al.. (2017). Abstract 4596: Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads alter the tumor immune microenvironment and synergize with multiple immunotherapies. Cancer Research. 77(13_Supplement). 4596–4596. 1 indexed citations
5.
Rios‐Doria, Jonathan, Nicholas M. Durham, Leslie Wetzel, et al.. (2015). Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models. Neoplasia. 17(8). 661–670. 146 indexed citations
6.
Leow, Ching Ching, Ivan Inigo, Suneetha B. Thomas, et al.. (2013). Abstract A49: Anti-DLL4 antibodies inhibit cancer stem cells in small cell lung cancer.. Molecular Cancer Therapeutics. 12(11_Supplement). A49–A49. 1 indexed citations
7.
Jenkins, David W., Haihong Zhong, Ching Ching Leow, et al.. (2013). Abstract 5098: A mouse DLL4 cross-reactive variant of MEDI0639 disrupts functional vessel formation and inhibits tumor growth in preclinical models.. Cancer Research. 73(8_Supplement). 5098–5098. 1 indexed citations
8.
Chesebrough, Jon, Sally‐Ann Ricketts, Margaret H. Veldman-Jones, et al.. (2011). Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth. Cancer Research. 71(3). 1029–1040. 105 indexed citations
9.
10.
Vogt, Andreas, Takanori Adachi, Alexander P. Ducruet, et al.. (2001). Spatial Analysis of Key Signaling Proteins by High-content Solid-phase Cytometry in Hep3B Cells Treated with an Inhibitor of Cdc25 Dual-specificity Phosphatases. Journal of Biological Chemistry. 276(23). 20544–20550. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manuela Lacerda Breakdown of academic impact, for papers by Kirat Kumar Ganguly Breakdown of academic impact, for papers by Margreet Lang Breakdown of academic impact, for papers by Mariam Gachechiladze Breakdown of academic impact, for papers by Caterina Malcontenti‐Wilson Breakdown of academic impact, for papers by Linda Mooberry Breakdown of academic impact, for papers by Vasilios Papavasiliou Breakdown of academic impact, for papers by Kian Kani Breakdown of academic impact, for papers by Camilla Hofström Breakdown of academic impact, for papers by Katrin Rabold
Rankless by CCL
2026